Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, continues to operate and supply product to the medical community through the global coronavirus crisis and has been preparing for the anticipated surge in demand for surgical procedures when normal operations resume.
Despite the COVID-19 pandemic and its effects on the healthcare sector globally, Biogennix has remained functional while taking all necessary measures to keep its team safe. Biogennix is diligently working to continue supplying existing products to customers, including AgilonTM moldable bone grafting product, which last month received FDA 510(k) clearance for an expanded indication to include the posterior lateral spine. Biogennix continues to manufacture and ship Agilon for emergency procedures, along with its other products, Morpheus and osteoSPAN.
Biogennix has also been using this time to continue working on new and novel products for the future.
“Although we are all currently faced with this extreme challenge, the healthy structure of our organization and our strong partnerships have enabled us to continue to provide product for emergency and necessary surgeries,” said Chris MacDuff, Biogennix’s CEO. “We are aware that this crisis has resulted in many elective surgeries being postponed as hospitals care for COVID-19 patients. However, we know this challenging time will subside. Our priorities today are to supply product for emergency surgeries that continue through this crisis, while preparing for the increased demand we will inevitably see once surgeries are rescheduled. We can assure our customers that we are utilizing this time to make sure that we have ample supply of Biogennix products as surgeons begin the rescheduling process.”
Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.
Biogennix® is a fully-integrated osteobiologics company headquartered in Irvine which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind natural bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005844/en/
Source: Biogennix
View this news release online at:
http://www.businesswire.com/news/home/20200414005844/en
